SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.02+1.4%2:11 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (20657)7/27/2006 10:02:29 PM
From: Ian@SI  Read Replies (1) of 52153
 
Not seeing anything on DJN... Yesterday Brean Murray started it at SELL.

Renovis 2Q Loss Narrows; Beats Street View >RNVS

DOW JONES NEWSWIRES
July 27, 2006 6:27 p.m.

Renovis Inc.'s (RNVS) second-quarter net loss narrowed to $5.83 million, or 20 cents a share, from $9.98 million, or 41 cents a share, a year ago as contract revenue rose sharply.

The South San Francisco, Calif., biopharmaceutical company's contract revenue jumped to $3.65 million from $656,000 a year ago.

On average, analysts expected a per-share loss of 30 cents on revenue of $2.23 million, according to a poll by Thomson First Call.

The company raised 2006 contract revenue guidance to a range of $10 million to $10.5 million from a range of $8.8 million to $9.2 million.

Renovis's share recently traded up 11 cents, or 1%, from the close to $10.70 after hours on Inet
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext